In the BioHarmony Drug Report Database
Insulin degludec
Tresiba (insulin degludec) is a protein pharmaceutical. Insulin degludec was first approved as Tresiba on 2013-01-20. It is used to treat hyperglycemia, type 1 diabetes mellitus, and type 2 diabetes mellitus in the USA. It has been approved in Europe to treat diabetes mellitus.
Trade Name
|
Tresiba |
|---|---|
Common Name
|
insulin degludec |
ChEMBL ID
|
CHEMBL2107869 |
Indication
|
diabetes mellitus, hyperglycemia, type 1 diabetes mellitus, type 2 diabetes mellitus |
Drug Class
|
Image (chem structure or protein)
